Health
Alebund Presents Phase 3 Trial Results of AP301 at the American Society of Nephrology (ASN) 2025 Congress
* Clinically and statistically significant superiority of AP301 maintenance dose versus ineffective low dose in reducing serum phosphate levels was established and AP301's efficacy is sustained throughout the 52 weeks of treatment. * The non-inferiority of AP301 to sevelamer carbonate in redu...
2025-11-07 20:00
1138
Smartee Celebrates the Opening of its 4.0 Digital Orthodontic Technology Exhibition Hall in Jiaxing, China
JIAXING, China, Nov. 7, 2025 /PRNewswire/ -- Smartee Denti-Technology has unveiled the Smartee Digital Orthodontic Technology Exhibition Hall, a 1,200-square-meter space dedicated to showcasing the company's innovations in clear aligner therapy and digital orthodontics. The event gathered a dist...
2025-11-07 18:05
1057
Harbour BioMed and Evinova China Announce Strategic AI Collaboration to Accelerate AI-Enabled Drug Development
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 7, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, andEvinova, a global ...
2025-11-07 14:00
1368
Volpara Now Operates Under Lunit Brand, Advancing a Unified Vision for AI Cancer Intelligence
The rebranding marks the first phase of Lunit's unified global identity, connecting breast health, AI detection, and precision oncology under one name. SEOUL, South Korea, Nov. 6, 2025 /PRNewswire/ -- Lunit (KRX: 328130), a leading provider of AI for cancer diagnostics and therapeutics, today ann...
2025-11-07 08:14
995
ACAAI 2025 | CS2015 (OX40L/TSLP Bispecific Antibody) Makes International Debut
SUZHOU, China, Nov. 6, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas, today announced that the Company will ...
2025-11-07 08:10
1073
OSR Holdings Announces Woori IO's Noninvasive Glucose Monitor Demonstrates High Accuracy and Precision in Company-Sponsored Pilot Study
BELLEVUE, Wash., Nov. 6, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH) today announced the key findings from a company-sponsored pilot study conducted by Woori IO, an OSR Company, in collaboration with Korea University Guro Hospital. The study, which took place fromMay 9 to September 12,...
2025-11-06 21:30
1238
KGC Launches Premium Ingredient Brand "G1899," for the Global B2B Health Ingredient Market
* KGC, a Global Health Leader, Expands into the B2B Ingredient Sector with Its Standardized Premium Brand "G1899" * Showcases "G1899" at the World's Largest Ingredient Exhibition, SSG 2025, Highlighting the Excellence of Red Ginseng * Demonstrates KGC's Quality Management Systems and Advanc...
2025-11-06 21:00
1099
International Symposium on Myofunctional Therapy Concludes Successfully in Shanghai, Strengthening Global Collaboration in Functional Orthodontics
SHANGHAI, Nov. 5, 2025 /PRNewswire/ -- The International Symposium on Myofunctional Therapy in Multidisciplinary Collaboration, hosted by the Chinese Association of Orofacial Myology (CHAOM) and supported by Smartee Denti-Technology, concluded successfully inShanghai. The event brought together ...
2025-11-06 15:35
891
The 2025 Chinese Congress on Holistic Integrative Oncology (CCHIO) will be held in Kunming, presenting a new landscape of integrated cancer prevention and treatment from a global perspective.
KUNMING, China, Nov. 5, 2025 /PRNewswire/ -- From November 6 to 9, 2025, the highly anticipated 2025 CCHIO will be grandly held in Kunming, the "Spring City". Hosted by the Chinese Anti-Cancer Association and the Secretariat of the Tengchong Scientists Forum Organizing Committee, co-hosted by the...
2025-11-06 10:58
932
Natural Field will Launch "Ashwagandha White Paper" at FTA Forum in Hangzhou
HANGZHOU, China, Nov. 5, 2025 /PRNewswire/ -- Natural Field, a leading Chinese supplier of botanical and functional ingredients, is set to release its highly anticipatedAshwagandha White Paper at the prestigious Food Technology and Application (FTA) Forum in Hangzhou. The forum, recognized as one...
2025-11-05 23:00
822
IDT Biologika Accelerates Global CDMO Expansion Manufacturing capabilities highlighted through consecutive participation in WVC, CPHI and BIO-Europe 2025
* Showcased end-to-end, customized manufacturing capabilities covering vaccines, gene and immune therapeutics * Strengthening global CDMO strategy through strategic synergy with SK bioscience * Sustainable growth expected, backed by European commercial manufacturing infrastructure and regul...
2025-11-05 21:00
985
BioDlink Congratulates Lepu Biopharma on Securing Approval for the World's First Approved EGFR-Targeted ADC
* BioDlink helps Lepu Biopharma win China's marketing approval for EGFR-targeted ADC treating recurrent or metastatic nasopharyngeal carcinoma * This Becotatug Vedotin injection approval is BioDlink's first commercial ADC manufacturing initiative worldwide, validating its complex biologics co...
2025-11-05 21:00
1014
Nona Biosciences Announces Expansion of Collaboration with Umoja Biopharma to Advance In Vivo CAR-T Cell Therapies
CAMBRIDGE, Mass., Nov. 5, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to I™), today announced an evaluation and license agreement with Umoja Biopharma ("Umoja"), the clinical-stage leader of in vivo cell therapies that...
2025-11-05 20:07
792
HanchorBio Presents Preclinical Data on HCB301 at SITC 2025
HCB301 is a first-in-class tri-specific immunotherapy targeting SIRPα-CD47, PD-1/PD-L1, and TGFβ; it shows potent macrophage activation, T-cell restoration, and tumor microenvironment remodeling in preclinical solid tumor models. TAIPEI, SHANGHAI, and SAN FRANCISCO, Nov. 5, 2025 /PRNewswire/ -- ...
2025-11-05 20:00
966
Zepp Health Corporation Reports Third Quarter 2025 Unaudited Financial Results
MILPITAS, Calif., Nov. 4, 2025 /PRNewswire/ -- Zepp Health Corporation ("Zepp" or the "Company") (NYSE: ZEPP) today announced its unaudited financial results for the third quarter of 2025. Third Quarter 2025 Financial and Operating Highlights: * Revenue reached US$75.8 million, representing 78...
2025-11-05 09:15
2069
Health In Tech Announces New Davos 2026 Panel: "First Ladies: Backing Women Who Build" Featuring Cherie Blair CBE, KC
STUART, Fla., Nov. 4, 2025 /PRNewswire/ -- Health In Tech (Nasdaq: HIT), an Insurtech platform company backed by third-party AI technology, today announced an expansion of its agenda for the Independent InsurTech Summit to be held during World Economic Forum Week 2026 inDavos, Switzerland. Fol...
2025-11-05 07:48
2039
Grit Biotherapeutics Invited to Deliver Oral Presentation at ASH 2025 on Breakthrough In Vivo CAR-T Therapy GT801
BEIJING, Nov. 4, 2025 /PRNewswire/ -- Grit Biotherapeutics Co., Ltd. ("Grit Bio "), a leading clinical-stage biopharmaceutical company pioneering next-generation immunotherapies,today announced that its groundbreaking GT801 in vivo CAR-T program has been selected for an oral presentation at the u...
2025-11-04 21:15
1272
LakeShore Biopharma Enters into Definitive Agreement for Going-Private Transaction
BEIJING, Nov. 4, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd ("LakeShore Biopharma" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics fo...
2025-11-04 20:04
1824
Sky Labs Attracts Investment With Omron Subsidiary 'OMRON VENTURES'
Global blood pressure monitoring No. 1 OMRON Healthcare signs strategic partnership MoU SEOUL, South Korea, Nov. 4, 2025 /PRNewswire/ -- On November 4, 2025, Sky Labs announced that it had attracted investments with OMRON Ventures(OVC: Minato-ku, Tokyo), Omron Group's enterprise-led venture capit...
2025-11-04 19:25
849
CARsgen Announces Positive Clinical Data for Allogeneic CAR-T Products CT0596 and CT1190B
SHANGHAI, Nov. 3, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces clinical data for CT0596, an allogeneic BCMA-targeting CAR-T product candidate developed on its proprietary THANK-u Plus™ ...
2025-11-03 22:15
1560
Week's Top Stories
Most Reposted
SGTraDex and IMDA Receive Pro-Enterprise Impact & Partnership Award for Interoperable Digital Documents Against Payment Trade Cooperation
[Picked up by 313 media titles]
2025-11-25 15:37
Senetas and Nokia Announce Strategic Alliance to Secure Mission-Critical Networks for Defence and Government
[Picked up by 311 media titles]
2025-11-27 07:25SpeQtre, the entanglement-based quantum comms demonstrator satellite, is now on orbit
[Picked up by 290 media titles]
2025-11-29 09:00
HOTEL GROOVE SHINJUKU strengthens its services for deaf and hard of hearing guests
[Picked up by 289 media titles]
2025-11-25 10:00
Pop the 90s: The Westin Surabaya and Four Points Pakuwon Indah Welcomes 2026 with a Spectacular Live Show Featuring Project Pop
[Picked up by 285 media titles]
2025-11-26 10:49
Most Read
LightInTheBox to Hold 2025 Annual General Meeting on December 19, 2025
2025-11-25 21:20
2613
MINISO Unveils Australia's First and Largest MINISO LAND Flagship at Sydney Chatswood
2025-11-27 18:56
2032
